RxDoctor Payments Data

Delina Davis-Cooley, PA

Medical · Rich Square, NCNPI 1508844358

Payments from drug & device makers

$5,785in general payments, 2019–2025

Across 357 payments — averaging $16.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$805
  • GSK$680
  • Novo Nordisk$464
  • Lilly USA, LLC$433
  • Pfizer$385
  • Boehringer Ingelheim$370
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$5,785100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,785 in reported general payments places this provider in the 85th percentile of 878 medical providers in North Carolina.

See all medical providers in North Carolina

Medicare billing

Part B allowed, 2024
$64,975
Medicare patients
191
Services billed
1,640

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide132$140,182
LinzessLinaclotide101$83,466
RybelsusSemaglutide71$77,128
FarxigaDapagliflozin Propanediol92$73,980
Trelegy ElliptaFluticasone/Umeclidin/Vilanter62$58,679
MounjaroTirzepatide43$56,025
TradjentaLinagliptin46$48,881
XareltoRivaroxaban58$42,530
JardianceEmpagliflozin40$41,320
EliquisApixaban46$39,138
Repatha SureclickEvolocumab50$36,094
GlyxambiEmpagliflozin/Linagliptin35$34,545
Breztri AerosphereBudesonide/Glycopyr/Formoterol36$33,992
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr50$29,027
Tresiba Flextouch U-200Insulin Degludec24$25,034

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$464$217,310203 claims
Boehringer IngelheimTradjenta, Jardiance, Glyxambi$370$124,745121 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Bevespi Aerosphere$805$124,037174 claims
GSKTrelegy Ellipta, Anoro Ellipta, Shingrix$680$95,570147 claims
AbbVieLinzess$219$83,466101 claims
Lilly USA, LLCMounjaro$433$56,02543 claims
Johnson & JohnsonXarelto, Invokana$204$52,01371 claims
PfizerEliquis, Abrysvo$385$48,37975 claims
MerckJanuvia$133$21,97626 claims
Astellas Pharma US IncMyrbetriq$45$14,13719 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$16$2,73611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 878 medical providers in North Carolina.

Other medical in Rich Square

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →